{'fraction_non_alphanumeric': 0.0178988326848249, 'fraction_numerical': 0.01556420233463035, 'mean_word_length': 5.398009950248756, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Differential expression of microtubule associated protein 1 light chain 3 gamma in cancers of the breast.

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding microtubule associated protein 1 light chain 3 gamma, MAP1LC3C, when comparing primary tumors of the breast to the tissue of origin, the normal breast. MAP1LC3C was also differentially expressed in lymph node metastasis in human breast cancer. MAP1LC3C mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of MAP1LC3C in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, HER2+, and normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. MAP1LC3C may be of relevance to initiation, maintenance or progression of cancers of the female breast.